Opens in a new tab
Monday, 16 November 2026
EVIDENCE. INTERPRETED.
Policy & Acquisitions

Mergers & Acquisitions

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in Mergers & Acquisitions

214 stories · every one Fact-Checked
Illustration of Entera Bio's investigational oral osteoporosis therapy EB613 with bone structure and oral peptide tablet representing Phase 3 clinical development supported by $275 million financing.Mergers & AcquisitionsEntera Bio Positions EB613 for Phase 3 Osteoporosis StudiesEntera Bio has raised $275 million through an oversubscribed private placement to fully fund Phase 3 registrational studies of EB613, an investigational oral PTH(1-34) therapy for osteoporosis.28 Jul 2026 · 3 min read
Fact-Checked
Illustration of antisense oligonucleotide therapy targeting the RNU4-2 gene mutation associated with ReNU syndrome through the BioMarin and n-Lorem collaboration.Mergers & AcquisitionsBioMarin, n-Lorem Advance First Mutation-Targeted Therapy for Newly Discovered ReNU SyndromeBioMarin and the n-Lorem Foundation have entered a global collaboration to develop the first investigational antisense oligonucleotide (ASO) therapy for ReNU syndrome.28 Jul 2026 · 3 min read
Fact-Checked
argenx acquires Forte Biosciences for $2.2 billion to add the first-in-class anti-CD122 antibody FB102 for autoimmune diseases including vitiligo and celiac disease.Mergers & Acquisitionsargenx Adds First-in-Class FB102 Through $2.2B Forte Biosciences Acquisitionargenx has agreed to acquire Forte Biosciences in a $2.2 billion all-cash deal, adding FB102, a first-in-class anti-CD122 antibody that showed positive Phase 1b results in vitiligo and…28 Jul 2026 · 3 min read
Fact-Checked
Illustration of YB-101 anti-TSHR monoclonal antibody targeting thyroid stimulating hormone receptor in Graves' disease and thyroid eye disease following Phase 2 clinical trial initiation.Mergers & AcquisitionsYarrow Bioscience Initiates Phase 2 Trial of Anti-TSHR Antibody YB-101 for Graves’ Disease and Thyroid Eye Disease Following VYNE MergerYarrow Bioscience has initiated patient dosing in a Phase 2a/2b trial of YB-101, a potential first-in-class anti-TSHR monoclonal antibody for Graves’ disease and thyroid eye disease.27 Jul 2026 · 3 min read
Fact-Checked
Arcus Biosciences and Summit Therapeutics launch clinical trial evaluating casdatifan plus ivonescimab for first-line metastatic clear cell renal cell carcinoma.Mergers & AcquisitionsArcus and Summit Launch Casdatifan–Ivonescimab Trial in Metastatic Kidney CancerArcus Biosciences and Summit Therapeutics launch clinical trial evaluating casdatifan plus ivonescimab for first-line metastatic clear cell renal cell carcinoma.23 Jul 2026 · 3 min read
Fact-Checked
Illustration of Halozyme and Incyte collaboration to develop an ENHANZE-enabled subcutaneous formulation of INCA033989 for mutant CALR-positive myeloproliferative neoplasms.Mergers & AcquisitionsHalozyme and Incyte Partner to Advance Subcutaneous INCA033989 for mutCALR-Positive Myeloproliferative NeoplasmsHalozyme Therapeutics has entered a global collaboration and license agreement with Incyte to develop ENHANZE-enabled subcutaneous formulations of the investigational anti-mutCALR antibody INCA033989 for myeloproliferative neoplasms, with the…21 Jul 2026 · 3 min read
Fact-Checked
bayer-henry-ford-health-strategic-clinical-trials-partnershipClinical TrialsBayer Partners with Henry Ford Health to Expand Clinical TrialsBayer and Henry Ford Health have launched a strategic research partnership to expand patient access to clinical trials across cardiovascular and renal diseases, oncology, and women’s health.18 Jul 2026 · 4 min read
Fact-Checked
Illustration of AI-powered de novo antibody discovery representing the collaboration between Chai Discovery and argenx to accelerate immunology drug development.Mergers & AcquisitionsChai Discovery and argenx Partner to Accelerate AI-Driven De Novo Antibody DiscoveryChai Discovery has partnered with argenx to apply its generative AI platform for de novo antibody discovery.16 Jul 2026 · 3 min read
Fact-Checked
Illustration of multispecific T-cell engager antibodies targeting immune cells, representing the AbCellera and Vertex Pharmaceuticals collaboration to develop novel therapies for autoimmune diseases.Mergers & AcquisitionsLilly Acquires AtaiBeckley to Advance BPL-003 for Treatment-Resistant DepressionEli Lilly has agreed to acquire AtaiBeckley in a transaction valued at up to $3.8 billion, strengthening its neuroscience pipeline with BPL-003, an FDA Breakthrough Therapy-designated intranasal 5-MeO-DMT…16 Jul 2026 · 4 min read
Fact-Checked
Novartis and Chai Discovery collaborate to use AI-powered molecular design and the Chai-3 platform to accelerate therapeutic antibody discovery across multiple disease targets.Mergers & AcquisitionsNovartis Partners With Chai Discovery to Advance AI Antibody DiscoveryNovartis has partnered with Chai Discovery to integrate the company’s Chai-3 artificial intelligence platform into therapeutic antibody discovery.14 Jul 2026 · 3 min read
Fact-Checked
Illustration of Spero Therapeutics and Innovent Biologics licensing agreement for IBI355 (SP001), an investigational anti-CD40L monoclonal antibody entering Phase 2 development for IgG4-related disease and Sjögren's disease.Mergers & AcquisitionsSpero Secures Global Rights to Innovent’s Anti-CD40L Antibody IBI355 in Up to $1.1B DealSpero Therapeutics has secured worldwide rights outside Greater China to Innovent Biologics’ investigational anti-CD40L antibody IBI355 under a licensing agreement worth up to $1.1 billion.14 Jul 2026 · 4 min read
Fact-Checked
AstraZeneca licenses Zegfrovy (sunvozertinib) from Dizal to expand treatment options for EGFR exon 20 insertion-positive non-small cell lung cancer worldwide.Mergers & AcquisitionsAstraZeneca Licenses Zegfrovy from Dizal in Up to $1.5 Billion Deal to Expand EGFR-Mutated Lung Cancer PortfolioAstraZeneca has licensed global rights to Zegfrovy (sunvozertinib) from Dizal in a deal valued at up to $1.5 billion.14 Jul 2026 · 3 min read
Fact-Checked
Page 7 of 18